DM
TGTX icon

Deerfield Management’s TG Therapeutics TGTX Stock Holding History

Deerfield Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,478
Closed -$268K – 408
2024
Q3 		$268K Buy
+11,478
New +$251K ﹤0.01% 395
2022
Q4 		– Sell
-2,677,500
Closed -$15.9M – 121
2022
Q3 		$15.9M Hold
2,677,500
– – 0.32% 69
2022
Q2 		$11.4M Buy
+2,677,500
New +$16.7M 0.23% 75
2017
Q2 		– Sell
-700,000
Closed -$8.15M – 96
2017
Q1 		$8.15M Buy
+700,000
New +$5.02M 0.31% 78

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Deerfield Management's TGTX Position: Q4 2024 in Review

Deerfield Management sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 11,478 shares — an estimated $268K sold.

Deerfield Management first reported a position in TGTX in Q1 2017 and held it in 4 quarters. The position peaked at $15.9M in Q3 2022. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Deerfield Management reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Deerfield Management sold 11,478 TG Therapeutics shares in Q4 2024, an estimated $268K.
  • Deerfield Management first reported a position in TG Therapeutics in Q1 2017 and held it in 4 quarters.
  • Deerfield Management's TG Therapeutics position peaked at $15.9M in Q3 2022.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.